CNP-106

· COUR Pharmaceutical Development Company, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CNP-106, covering 2025-02-13 to 2025-02-13. Get the full timeline:

Most recent: Clinical Trial Update: Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis [Phase 1, Phase 2]

See pricing